239 related articles for article (PubMed ID: 24565450)
1. Severe asthma: an expanding and mounting clinical challenge.
Bell MC; Busse WW
J Allergy Clin Immunol Pract; 2013 Mar; 1(2):110-21; quiz 122. PubMed ID: 24565450
[TBL] [Abstract][Full Text] [Related]
2. Treating Moderate-to-Severe Allergic Asthma with a Recombinant Humanized Anti-IgE Monoclonal Antibody (Omalizumab).
D'Amato G; Bucchioni E; Oldani V; Canonica W
Treat Respir Med; 2006; 5(6):393-8. PubMed ID: 17154668
[TBL] [Abstract][Full Text] [Related]
3. Omalizumab decreases exacerbation frequency, oral intake of corticosteroids and peripheral blood eosinophils in atopic patients with uncontrolled asthma.
Pelaia G; Gallelli L; Romeo P; Renda T; Busceti MT; Proietto A; Grembiale RD; Marsico SA; Maselli R; Vatrella A
Int J Clin Pharmacol Ther; 2011 Dec; 49(12):713-21. PubMed ID: 22122813
[TBL] [Abstract][Full Text] [Related]
4. Long-term omalizumab treatment in severe allergic asthma: the South-Eastern Mediterranean "real-life" experience.
Tzortzaki EG; Georgiou A; Kampas D; Lemessios M; Markatos M; Adamidi T; Samara K; Skoula G; Damianaki A; Schiza S; Tzanakis N; Siafakas NM
Pulm Pharmacol Ther; 2012 Feb; 25(1):77-82. PubMed ID: 22155001
[TBL] [Abstract][Full Text] [Related]
5. Anti-IgE therapy with omalizumab for severe asthma: current concepts and potential developments.
Pelaia G; Vatrella A; Busceti MT; Gallelli L; Terracciano R; Maselli R
Curr Drug Targets; 2015; 16(2):171-8. PubMed ID: 25523898
[TBL] [Abstract][Full Text] [Related]
6. Treatment of childhood asthma with anti-immunoglobulin E antibody (omalizumab).
Milgrom H; Berger W; Nayak A; Gupta N; Pollard S; McAlary M; Taylor AF; Rohane P
Pediatrics; 2001 Aug; 108(2):E36. PubMed ID: 11483846
[TBL] [Abstract][Full Text] [Related]
7. A recombinant humanized anti-IgE monoclonal antibody (omalizumab) in the therapy of moderate-to-severe allergic asthma.
D'Amato G; Piccolo A; Salzillo A; Noschese P; D'Amato M; Liccardi G
Recent Pat Inflamm Allergy Drug Discov; 2007 Nov; 1(3):225-31. PubMed ID: 19075985
[TBL] [Abstract][Full Text] [Related]
8. Effect of omalizumab as add-on therapy on asthma-related quality of life in severe allergic asthma: a Brazilian study (QUALITX).
Rubin AS; Souza-Machado A; Andradre-Lima M; Ferreira F; Honda A; Matozo TM;
J Asthma; 2012 Apr; 49(3):288-93. PubMed ID: 22356355
[TBL] [Abstract][Full Text] [Related]
9. Omalizumab for the treatment of severe persistent allergic asthma: a systematic review and economic evaluation.
Norman G; Faria R; Paton F; Llewellyn A; Fox D; Palmer S; Clifton I; Paton J; Woolacott N; McKenna C
Health Technol Assess; 2013 Nov; 17(52):1-342. PubMed ID: 24267198
[TBL] [Abstract][Full Text] [Related]
10. Effectiveness of omalizumab in a patient with severe asthma, low serum IgE level, and lack of sensitized allergens induced by oral steroid therapy: the usefulness of impulse oscillation for assessment of omalizumab therapy.
Matsuno O; Komori C; Hang Y; Matsumoto T; Minamoto S
J Asthma; 2012 Oct; 49(8):839-42. PubMed ID: 22920591
[TBL] [Abstract][Full Text] [Related]
11. Omalizumab for the treatment of severe persistent allergic asthma in children aged 6-11 years: a NICE single technology appraisal.
Burch J; Griffin S; McKenna C; Walker S; Paton J; Wright K; Woolacott N
Pharmacoeconomics; 2012 Nov; 30(11):991-1004. PubMed ID: 22950547
[TBL] [Abstract][Full Text] [Related]
12. Anti-IgE for chronic asthma in adults and children.
Walker S; Monteil M; Phelan K; Lasserson TJ; Walters EH
Cochrane Database Syst Rev; 2004; (3):CD003559. PubMed ID: 15266491
[TBL] [Abstract][Full Text] [Related]
13. Omalizumab: an update on efficacy and safety in moderate-to-severe allergic asthma.
Chipps BE; Figliomeni M; Spector S
Allergy Asthma Proc; 2012; 33(5):377-85. PubMed ID: 23026179
[TBL] [Abstract][Full Text] [Related]
14. A study into efficacy of omalizumab therapy in patients with severe persistent allergic asthma at a tertiary referral centre for asthma in Ireland.
Subramaniam A; Al-Alawi M; Hamad S; O'Callaghan J; Lane SJ
QJM; 2013 Jul; 106(7):631-4. PubMed ID: 23550166
[TBL] [Abstract][Full Text] [Related]
15. Concomitant asthma medications in moderate-to-severe allergic asthma treated with omalizumab.
Chen H; Eisner MD; Haselkorn T; Trzaskoma B
Respir Med; 2013 Jan; 107(1):60-7. PubMed ID: 23083840
[TBL] [Abstract][Full Text] [Related]
16. [Retrospective analysis of omalizumab in patients with severe allergic asthma].
Padullés Zamora N; Comas Sugrañes D; Méndez Cabaleiro N; Figueras Suriol A; Jodar Masanes R
Farm Hosp; 2013; 37(5):399-405. PubMed ID: 24128103
[TBL] [Abstract][Full Text] [Related]
17. Anti-IgE and chemotherapy: a critical appraisal of treatment options for severe asthma.
Walters EH; Walters JA; Wood-Baker R
Expert Opin Pharmacother; 2007 Apr; 8(5):585-92. PubMed ID: 17376014
[TBL] [Abstract][Full Text] [Related]
18. Omalizumab in the treatment of asthma.
Tan R; Corren J
Expert Rev Respir Med; 2011 Dec; 5(6):747-56. PubMed ID: 22082161
[TBL] [Abstract][Full Text] [Related]
19. Population-based efficacy modeling of omalizumab in patients with severe allergic asthma inadequately controlled with standard therapy.
Zhu R; Zheng Y; Putnam WS; Visich J; Eisner MD; Matthews JG; Rosen KE; D'Argenio DZ
AAPS J; 2013 Apr; 15(2):559-70. PubMed ID: 23413101
[TBL] [Abstract][Full Text] [Related]
20. Anti-IgE for chronic asthma.
Walker S; Monteil M; Phelan K; Lasserson TJ; Walters EH
Cochrane Database Syst Rev; 2003; (3):CD003559. PubMed ID: 12917972
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
